Trial Profile
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m2 and at 25 mg/m2 Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PROSELICA
- Sponsors Sanofi
- 01 Jul 2021 Results of post-hoc analysis of two studies (PROSELICA (NCT01308580) and FIRSTANA (NCT01308567)) assessing patient-reported health-related quality of life (HRQL), published in the Oncologist.
- 31 May 2020 Results of post-hoc analysis evaluating the influence of progression type at randomization on outcomes presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2019 Results assessing cell-free DNA as a biomarker for taxane response by using data from two studies (PROSELICA and FIRSTANA) presented at the 55th Annual Meeting of the American Society of Clinical Oncology